Endo Comorbidities Evaluation

---
name: endo-comorbidities-evaluation
description: The skill evaluates all patients with acromegaly for hypertension, diabetes mellitus, cardiovascular disease, osteoarthritis, and sleep apnea at initial assessment. It is triggered by a new diagnosis of acromegaly or when a patient presents for baseline endocrine workup.
---

# Evaluate comorbidities in all acromegaly patients

## STEP 1 — Gather Information
Confirm acromegaly diagnosis (elevated IGF-1 with lack of GH suppression after glucose load). Collect history: blood pressure, diabetic symptoms, cardiovascular symptoms (chest pain, dyspnea), joint pain/stiffness, snoring, daytime somnolence. Perform exam: BP, BMI, joint inspection, neck circumference. Order labs: fasting glucose/HbA1c, lipid panel, basic metabolic panel.

## STEP 2 — Rule In / Rule Out
Is acromegaly biochemically confirmed?  
- Yes → Proceed to comorbidity evaluation.  
- No → Consider alternative diagnoses; do not apply this comorbidity pathway.

## STEP 3 — Classify or Stratify
Screen results for each comorbidity:  
- Hypertension: BP ≥130/80 mmHg or on treatment.  
- Diabetes: HbA1c ≥6.5% or fasting glucose ≥126 mg/dL.  
- Cardiovascular disease: history of MI, stroke, or abnormal stress test/echo.  
- Osteoarthritis: joint pain with crepitus or radiographic changes.  
- Sleep apnea: STOP-BANG ≥3 or witnessed apneas; refer for polysomnography.

## STEP 4 — Decide
For each identified comorbidity, initiate guideline-directed management:  
- Hypertension: start ACEi/ARB, lifestyle.  
- Diabetes: metformin ± other agents.  
- CVD: cardiology referral, aspirin/statin as indicated.  
- Osteoarthritis: acetaminophen/NSAID, PT, weight loss.  
- Sleep apnea: CPAP titration after sleep study.

## Clinical Guardrails / Mimics / Pitfalls
Do not attribute all symptoms to acromegaly without evaluating comorbidities separately. Manage each comorbidity per disease-specific guidelines; do not delay definitive acromegaly therapy while completing screening. Avoid assuming normal labs exclude disease in early stages.

## Concrete Clinical Example
A 48-year-old with newly diagnosed acromegaly (IGF-1 450 ng/mL, no GH suppression) presents for initial workup. Screening shows BP 152/94 mmHg, HbA1c 7.1%, triglycerides 210 mg/dL, bilateral knee crepitus, and spouse-reported snoring with apneas. Diagnoses: hypertension, type 2 diabetes, hyperlipidemia, osteoarthritis, probable OSA. Treatment: lisinopril, metformin, atorvastatin, NSAID PRN, and sleep study with CPAP if OSA confirmed.

**Source:** Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700